Role of lipoprotein-associated phospholipase A2 in atherosclerosis

被引：0
|
作者：
Shahar Lavi
Joerg Herrmann
Ronit Lavi
Joseph P. McConnell
Lilach O. Lerman
Amir Lerman
机构：
[1] Mayo Clinic,Division of Cardiovascular Diseases
来源：
Current Atherosclerosis Reports | 2008年 / 10卷
关键词：
Acute Coronary Syndrome; Stable Coronary Artery Disease; Arterioscler Thromb Vasc Biol; Coronary Endothelial Dysfunction; Stable Coronary Disease;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a biomarker that can be used to assess the risk for cardiovascular disease and events. In addition to being a useful marker of a risk factor, several studies suggest that Lp-PLA2 has a pathophysiologic role in the atherosclerotic disease process. In this article, we review this aspect and its therapeutic implications.
引用
收藏
相关论文
共 50 条
  • [31] Association between the Lipoprotein-Associated Phospholipase A2 Activity and the Progression of Subclinical Atherosclerosis
    Liu, Jing
    Wang, Wei
    Qi, Yue
    Yong, Qiang
    Zhou, Guanghua
    Wang, Miao
    Sun, Jiayi
    Liu, Jun
    Jia, Zhangrong
    Zhao, Dong
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2014, 21 (06) : 532 - 542
  • [32] Expression and purification of lipoprotein-associated phospholipase A2, a key enzyme involved in atherosclerosis
    Zhang, Fu-Jun
    Cai, Mao-Jun
    Shen, Jing-Kang
    Wang, Yi-Ping
    ACTA PHARMACOLOGICA SINICA, 2006, 27 (06) : 679 - 684
  • [33] Lipoprotein-Associated Phospholipase A2 Activity Predicts Progression of Subclinical Coronary Atherosclerosis
    Kinney, Gregory L.
    Snell-Bergeon, Janet K.
    Maahs, David M.
    Eckel, Robert H.
    Ehrlich, James
    Rewers, Marian
    Hokanson, John E.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2011, 13 (03) : 381 - 387
  • [34] Orally active inhibitors of lipoprotein-associated phospholipase A2 for the potential treatment of atherosclerosis
    Tranter, D
    DRUG DISCOVERY TODAY, 2001, 6 (06) : 324 - 324
  • [35] Expression and purification of lipoprotein-associated phospholipase A2, a key enzyme involved in atherosclerosis
    Fu-jun Zhang
    Mao-jun Cai
    Jing-kang Shen
    Yi-ping Wang
    Acta Pharmacologica Sinica, 2006, 27 : 679 - 684
  • [36] Plasma Lipoprotein-associated Phospholipase A2 in Patients with Metabolic Syndrome and Carotid Atherosclerosis
    Hui-ping Gong
    Yi-meng Du
    Li-na Zhong
    Zhao-qiang Dong
    Xin Wang
    Yong-jun Mao
    Qing-hua Lu
    Lipids in Health and Disease, 10
  • [37] Lipoprotein-associated phospholipase A2: The story continues
    Huang, Fubao
    Wang, Kai
    Shen, Jianhua
    MEDICINAL RESEARCH REVIEWS, 2020, 40 (01) : 79 - 134
  • [38] Lipoprotein-associated phospholipase A2 is associated with the risk of dementia
    van Oijen, M
    van der Meer, IM
    Hofman, A
    Witteman, JCM
    Koudstaal, PPJ
    Breteler, MMB
    NEUROLOGY, 2005, 64 (06) : A268 - A268
  • [39] Lipoprotein-associated phospholipase A(2) : role in atherosclerosis and utility as a cardiovascular biomarker
    Toth, Peter P.
    McCullough, Peter A.
    Wegner, Michael S.
    Colley, Kenneth J.
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2010, 8 (03) : 425 - 438
  • [40] Variability of lipoprotein-associated phospholipase A2 measurements
    McConnell, Joseph P.
    Jaffe, Allan S.
    CLINICAL CHEMISTRY, 2008, 54 (05) : 932 - 933
12345